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Abstract  Article Info 
Introduction: Cancer patients experience many symptoms. The symptoms have a major impact on Quality of 
Life (QoL) among patients with nasopharyngeal carcinoma. Diagnostic and treatment delays can be reduced to 
improve the prognoses of the cancer patients. Cancer waiting time may still be important as indicators of overall 
performance of a health service. 
Objective: The aim of this study was to investigate the association of waiting time for diagnosis with quality of 
life in nasopharyngeal carcinoma. 
Methods: A cohort survey was done in six months from July to December 2019. We conducted new patients 
whom never had any therapy from other care centers. Data were collected two times using the structured 
interview technique by using EORTC QLQ-C30 and QLQ-H&N43 questionnaires. We counted the time for 
diagnosis from the first time the patient came for diagnostic until the first therapy for the cancer. 
Results: The eligible samples were 24 patients. Their mean (SD) and median ages were 46.71 (10.1) and 49.0 
years respectively and waiting time for diagnosis was 34.2 (10.4) and 31.0 days. The patient’s scored <33.3 for 
global health status in first came to the hospital (pre-test) was 66.7%. In pre-test, diarrhea and constipation were 
the most disturbing symptoms and the post-test were loss of appetite and dyspnea. Time for diagnosis was 
statistically significant with global health (P<0.05). Global health has significant differences in the pre-test and 
post-test. 
Conclusion: The nasopharyngeal carcinoma patients in our institution had a worse quality of life regarding 
overall status. Waiting time for diagnosis has association with global health score in quality of life (QoL). 
Further research is required to investigate the clinical patient during waiting period for diagnosis. 
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1. INTRODUCTION 
Cancer-one of the non-communicable disease (NCD) is estimated 
to rank as the leading cause of death and the single most important 
barrier to increasing life expectancy in every country of the world [1]. 
Based on the World Health Organization (WHO) in 2015,  cancer is 
the first or second leading cause of death before age 70 years in 91 of 
172 countries [2]. Approximately 70% of deaths from cancer occur in 
low-and middle-income countries. Cancer is a burden for every 
country in the world [3].  
Nasopharyngeal carcinoma (NPC) is a malignancy with distinct 
geographical distribution commonly diagnosed in southern China and 
southeast Asia with the prevalence rate is 15-50 cases per 100,000 
people [4]-[5]. As a special type of head and neck cancer, NPC was 
the highest in new cases and mortality rates in the world. Based on 
GLOBOCAN 2018, the new cases was 129,079 cases and 72,987 
number of deaths [6]. The yearly incidence occurred varied among 
tumors but the overall data consistently identified NPC as the most 
common head and neck cancer in Indonesia for 10-years and is more 
common in men than women [7].  
Cancer patients experienced a variety of symptoms. Inadequate 
management of symptoms might disturb the performance of the daily 
activities of an individual. The symptoms have a major impact on 
Quality of Life (QoL) among patients with nasopharyngeal 
carcinoma. More symptoms by the patients have been associated with 
higher levels of emotional suffering, physical functioning, societal 
functioning, and global QOL [8]. Quality of life is an important aspect 
of cancer patient care. Cancer and its treatment can create difficulties 
in fulfilling the patient’s role as a family member such as the ability 
to work or participate in common social activities [9].  
The European Organization for Research and Treatment of 
Cancer (EORTC) quality of life questionnaire is an integrated 
system for assessing the quality of life associated with the health 
of cancer patients participating in international clinical trials. 
This questionnaire has been used extensively in cancer clinical 
trials by a large number of research groups and has been used in 
non-clinical trials [10, 11]. Assessment of quality of life for 
cancer patients usually uses the EORTC QLQ -C30 questionnaire 
(European Organization for Research and Treatment of Cancer 
Quality of Life Questionnaire-C30) while for head and neck tumor 
patients uses European Organization for Research and Treatment 
of Cancer Head and Neck Cancer Quality of Life Questionnaire 
(EORTC QLQ-H & N45).  
Measuring the quality of life is needed for health workers to make 
it easier to find problems experienced by patients during therapy that 
makes it easier for health workers to communicate and educate 
patients [12, 13]. A few researchers focused on the quality of life just 
in cancer for general in Indonesia [12-16]. But in this study, we also 
assessed the quality of life in head and neck cancer. Treatment of 
cancer must be fast and precise because it is closely related to the 
patient's quality of life. The faster handling of patients will prevent a 
decrease in quality of life. Therefore, the aim of this study was to 
investigate the association of waiting time for diagnosis with quality 












2. MATERIALS AND METHODS 
2.1 Study design dan participant 
A survey-based study was carried out in the Oncology Department, 
especially in ear, nose, and throat policlinic at National Cancer Center – 
Dharmais Cancer Center Hospital, Indonesia. A cohort survey was done in 
six months from July to December 2019 in our institution. We conducted 
new patients whom never had any therapy from other care centers. Patients 
who have been diagnosed and had first therapy in another center were 
excluded from this study. 
The sampling technique used in this study was purposive sampling. 
Data were collected using the structured interview technique two times after 
obtaining permission from the respective hospital administrators and the 
ethics committee. First, we assessed in the first-time patients come into 
outpatients clinics (pre-test). And second, we interviewed when the patients 
have diagnosed and type of therapy (post-test). We counted the time for 
diagnosis from the first time the patient came for diagnostic until the first 
therapy for the cancer. 
 
2.2 Questionnaires  
The EORTC quality of life questionnaire (QLQ) is an integrated system 
for assessing the health-related quality of life (QoL) of cancer patients 
participating in international clinical trials. The core questionnaire, the 
QLQ-C30, is the product of more than a decade of collaborative research. 
Following its general release in 1993, the QLQ-C30 has been used in a wide 
range of cancer clinical trials, by a large number of research groups; it has 
additionally been used in various other, non-trial studies [17]. Patients 
include in this study were asked to fill questionnaires in Indonesian language 
[18]. Some studies has assessment these tools for validity and reliability in 
varied patients in the world [18-21]. 
The EORTC QLQ-C30 has 30 items arranged into nine scales and six 
single items. The scales are divided into five function scales (physical, role, 
cognitive, emotional, and social function); three symptom scales (fatigue, 
pain, and nausea or vomiting) and one global health status/quality of life 
scale. The six single items address specific symptoms: dyspnea, appetite 
loss, insomnia, constipation, and diarrhea, and one question addressing the 
financial impact of the disease. Each item has four response alternatives: 1) 
“not at all”, 2) “a little”, 3) “quite a bit”, and 4) “very much”, except for the 
global health status/quality of life scale, which has response options ranging 
from 1) “very poor” to 7) “excellent”. 
The QLQ-HN43 consists of 43 items with a response format (4-point Likert 
scale). The head & neck cancer module is meant for use among a wide range 
of patients with head & neck cancer, varying in disease stage and treatment 
modality. The head & neck cancer module incorporates multi-item scales 
that assess pain, swallowing, senses (taste and smell), speech, social eating, 
social contact, mouth, coughing, wounds healing, weight loss, skin problem, 
anxiety, numbness in hands or feet, and sexuality [17]. Each item has four 
response alternatives: 1) “not at all”, 2) “a little”, 3) “quite a bit”, and 4) 
“very much”. In this study, the part of sexual behavior not used with 
permission from the research ethics committee of Dharmais Cancer Center 
Hospital. 
 
2.3 Statistical analysis 
All statistical procedures were performed in accordance with the 
instructions contained in the EORTC QLQ-C30 scoring manual [17]. The 
data analyzed in SPSS version 25. We calculated the relevant descriptive 
statistics for characteristics patients (age, gender, job, educational 
background, cancer staging, and waiting time for diagnosis) and the 
questionnaire items. Average values of descriptive methods, standard 
deviations for the continuous variables, while frequencies and percentages 
for the categorical variables were used to describe the data.  
Patients were divided into two groups according to their scores. The 
patients who scored <33 for the functional scales and the global QoL were 
considered problematic, while the patients who scored >66 were considered 
in good condition. For symptom scales, the score is reversed, i.e., the 
patients who scored <33 were considered in good condition and the patients 
who scored >66 were considered problematic [22, 23]. The spearman's 
correlation was used to identified correlation time diagnosis and items 
quality of life scales. The paired t-test was used for comparison first (pre-




Thirty-five patients completed the survey questionnaire. The eligible 
samples were 24 patients because six patients lost to follow up and three 
patients died. Their mean (SD) and median ages were 46.71 (10.1) and 49.0 
years respectively and waiting time for diagnosis was 34.2 (10.4) and 31.0 
days. Characteristics of patients according to their age, gender, job, 
educational background, and cancer staging are shown in Table 1, while 
assessment of the quality of life using EORTC QLQ-C30 and QLQ-H&N43 
questionnaire is mentioned in Table 2. 
Overall, for EORTC QLQ-C30, global health status was low in first 
come (pre-test) to the hospital but better in the last (post-test). Functional 
scales in most were moderate-to-high for most items in the pre-test but 
decreased in the post-test.  Symptoms scales were moderate-to-high in pre-
test and post-test.  Similarly, a higher score in functional scales indicated 
better QoL. On the other hand, higher scores in symptoms scales (either 
QLQ-C30 and QLQ-H&N43) showed worse QoL [22]. 
Table 1. Characteristics of patients 
Variable n (%) 
Age  
≤ 45 years 9 (37.5) 
> 45 years 15 (62.5) 
Gender  
Male 8 (33.3) 
Female 16 (66.7) 
Job  
Unemployed 15 (62.5) 
Employed 9 (37.5) 
Educational background  
Higher education (college graduate) 2 (8.3) 
Middle education (senior high school) 14 (58.3) 
Low education (elementary and junior high school) 8 (33.3) 
Cancer Staging  
Early stage (stage 1,2) 1 (4.2) 
Advanced stage (stage 3,4) 23 (95.8) 
Waiting time for diagnosis (mean; median; min-max) 34; 31; 17-55 (days) 
 
Most of the patients scored <33.3 (on a scale of 0-100) for global 
health status in first came to the hospital (pre-test), but increased 
score in waiting time for diagnosis. The cognitive functional is the 
most-highest scale, where >70% of patients scored >66.7 either in the 
pre-test and post-test. Diarrhea and constipation were the most 
disturbing symptoms in the first came to the hospital followed by loss 
of appetite and dyspnea in the post-test. For QLQ-H&N43, patients 
showed a higher score for teeth and skin problems, while the least 
score was anxiety (Table 2). 
Spearman's correlation indicated a correlation of waiting 
time for diagnosis with global health in QLQ -C30 (Table 3) and 
symptoms scales in QLQ-H&N43 (Table 4). Time for diagnosis 
was statistically significant with global health (p<0,05). Physical, 
role, emotional, cognitive, and social functioning have correlated 
significantly with global health (QoL) (Table 3). Based on QLQ -
H&N43, waiting time for diagnosis was statistically significant 
with symptoms in NPC mainly felt in the neck and shoulder. Table 
4 indicated that some symptoms scale has inte r-correlated that can 
decrease quality of life (QoL).  
Comparison of quality of life in NPC at first came to the hospital 
(pre-test) and after diagnosis is shown in Table 5. Global health has 
significant differences in the pre-test and post-test (mean difference            
=-14.9). All functional scales have significant differences, except 
emotional functioning. Symptoms scale in QLQ-C30, fatigue, loss of 
appetite, nausea, and vomiting have significant differences (P<0.05).  
Based on symptoms nasopharyngeal carcinoma in QLQ-H&N43 
almost all items have significant differences in pre -test and post-test. 
It signified that the treatment of cancer patients must be done faster 
because delayed treatment will increase symptoms that can decrease 
the quality of life of the patient. 
4. DISCUSSION 
Patients’ quality of life has become a major objective of care in oncology. 
This study showed that, overall, scores of global health status was low in first 
came to the hospital (pre-test) but increased in the last (post-test) and has 
differences significantly. Waiting time for diagnosis has statistically significant 
with global health. Quality of life in our patients increased in post-test because 







patients under treatment for improvement of general condition and reduce pain 
during waiting for diagnosis. In this study, mean of waiting time for diagnosis 
was 34 days (the fastest was 17 days) and have significant correlation with 
quality of life (QoL). In some countries, cancer waiting times standards for 
diagnosis was two weeks (14 days) and one month (31-day) from diagnosis to 
first treatment wait for all cancers [24-27].  
Diagnostic and treatment delays can be reduced to improve the 
prognoses of the cancer patients. In Dharmais Cancer Hospital, the patients 
who came for the first time to the hospital was in bad condition and without 
any staging. In result, global health status patients in the pre-test have worse 
score (under 50), so the doctor gave recovery treatment to the patients before 
done the staging process.  A limited number of studies have carried out 
regarding delays in diagnosis and treatment of cancer patients in developing 
countries. Study in Pakistan, delay treatment is associated with lack of 
awareness, low household income and difficulties in approaching the 
healthcare facilities [28]. The patient delay is responsible for the diagnosis 
of the disease at an advanced stage. Similarly, in our study that waiting time 
for diagnosis was caused by the worse condition of patients, lack of 
awareness, and financial difficulties. 
Cancer waiting time targets have been integrated into successive 
cancer strategies as indicators of cancer care quality. Cancer waiting time 
may still be important as indicators of overall performance of a health 
service, so should having targets for waiting time. It has set cancer apart 
from other diseases, enabling cancer patients to be treated more quickly. 
Delayed treatment would affect the outcomes [27]. So, the treatment of 
cancer patients must be quick in order to increase the quality of life. 
Functional scales in most were moderate-to-high for most items in 
the pre-test but low in the post-test. Symptoms scales were moderate-to-
high in both test (Table 2). These scores indicated worse QoL in our 
patients mainly in the first came to the hospital because 95% of patients 
in advanced stage. Cancer patients experience many symptoms affected 
their QoL [8]. Stage of cancer is also known to be associated with quality 
of life, and the advanced stage showed the low quality of life. The more 
severe the disease or higher the stage of cancer affects the worse quality 
of life. [29, 30].  
The most-highest score in functional scales was cognitive functioning 
and the lowest was role functioning. Better perceived cognitive function 
was associated with higher QOL scores. Receiving treatment for cancer 
patients reported a significant worsening of cognitive function over the 
course of treatment that was accompanied by depression and fatigue [31]. 
Decreased cognitive function following cancer diagnosis and subsequent 
treatment frequently are reported by survivors of cancer patients and are 
associated with significantly diminished quality of life [31, 32]. 
Diarrhea and constipation were the most disturbing symptoms in 
the first came to the hospital followed by loss of appetite  and dyspnea 
in the post-test. Appetite loss can be perceived as an indicator of both 
quality of life and cancer severity, and is independently linked to 
survival and correlates significantly with physical function. Appetite 
loss may, however, also be affected by secondary factors such as 
depression/psychosocial stress, nausea, constipation, taste alterations 
or pain [33].  
People with advanced cancer often notice changes in their appetite. 
This may be because of cancer itself, treatment, or other side effects such 
as tiredness, nausea or vomiting, taste changes, pain, lack of activity, or 
depression. A loss of appetite often leads to weight loss and malnutrition. 
Eating is very important to maintain the strength, function, and quality of 
life. Cancer-associated loss of appetite is not simple, the presence of 
cancer-associated anorexia was found to strongly influence patient 
satisfaction with their health and physical function [34].  
Dyspnea is a very common symptom in patients with advanced and 
terminal cancer, and its prevalence increases as death approach. In the 
cancer patient, dyspnea can be caused by the malignancy itself, therapies, 
comorbid medical conditions, as well as general muscle weakness/wasting. 
Dyspnea can also be caused by obstruction of the respiratory due to tumor 
swelling in the nasopharynx in patients with NPC [35].  
Our study limitation was not evaluated in detail such as prognostic, 
clinical factors and therapy for cancer. During waiting time for diagnosis, 
the doctor gave treatment to decreased the pain, so it can increase the 
quality of life in second measurement.  
5. CONCLUSION 
Our patients had a worse quality of life (QoL) regarding overall status 
as well as functional and symptoms scales. Waiting time for diagnosis has 
significant correlation with global health. In pre-test, diarrhea and 
constipation were the most disturbing symptoms. Besides, in the post-test, 
the most symptoms were loss of appetite and dyspnea. Symptoms scale in 
head and neck questionnaires, patients showed a higher score for teeth and 
skin problems, but the least score was anxiety. During the waiting period for 
diagnosis, it is possible to increase the stage of cancer or metastases, so it is 
necessary to have further research related to QoL, time, clinical patient and 
patient’s therapy.  
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Table 2. Assessment of quality of life in nasopharyngeal carcinoma by using EORTC QLQ-C30 and QLQ-H&N43 questionnaires 
Scales N No of items 
Means ± SD 95% CI N (%) Scoring <33.3 N (%) Scoring >66.7 
Pre Post Pre Post Pre Post Pre Post 
QLQ-C30 questionnaires           
Global health status/QoL 24 2 29.2 ± 16.7 44.1 ± 18.9 22.1 - 36.2 36.1 - 52.1 16 (66.7) 12 (50.0) 1 (4.2) 3 (12.5) 
Functional scales           
Physical functioning 24 5 72.2 ± 19.5 47.2 ± 19.4 63.9 - 80.5 39.1 - 55.4 1 (4.2) 7 (29.2) 18 (75.0) 6 (25.0) 
Role functioning 24 2 56.9 ± 31.8 33.3 ± 21.9 43.5 - 70.4 24.0 - 42.6 10 (41.7) 17 (70.8) 13 (54.2) 4(16.7) 
Emotional functioning 24 4 57.3 ± 26.4 54.5 ± 17.4 46.2 - 68.6 47.2 - 61.9 7 (29.2) 7 (29.2) 13 (54.2) 13 (54.2) 
Cognitive functioning 24 2 79.9 ± 24.6 68.7 ± 17.2 69.5 - 90.2 61.5 - 76.5 2 (8.3) 3 (12.5) 20 (83.3) 19 (79.2) 
Social functioning 24 2 70.1 ± 29.9 50.7 ± 18.7 57.5 - 82.8 42.8 - 58.6 5 (20.8) 8 (33.3) 17 (70.8) 10 (41.7) 
Symptoms scales           
Fatigue 24 3 48.6 ± 27.4 29.6 ± 19.0 37.1 - 60.2 21.6 - 37.6 8 (33.3) 13 (54.2) 11 (45.8) 0 (0,0) 
Nausea and vomiting 24 2 84.7 ± 27.8 63.9 ± 29.4 73.0 - 96.5 51.5 - 76.3 3 (12.5) 8 (33.3) 21 (87.5) 16 (66.7) 
Pain 24 2 42.4 ± 30.3 37.5 ± 30.4 29.6 - 55.2 24.7 - 50.3 12 (50.0) 12 (50.0) 8 (33.3) 7 (29.2) 
Dyspnea 24 1 75.1 ± 34.4 88.9 ± 21.2 60.5 - 89.5 79.9 - 97.9 4 (16.7) 2 (8.3) 20 (83.3) 22 (91.7) 
Insomnia 24 1 43.1 ± 39.9 44.5 ± 34.9 26.2 - 59.9 29.7 - 59.2 13 (54.2) 12 (50.0) 11 (45.8) 12 (50.0) 
Appetite loss 24 1 66.7 ± 38.1 33.3 ± 27.8 50.6 - 82.7 21.6 - 45.1 9 (37.5) 18 (75.0) 15 (62.5) 6 (25.0) 
Constipation 24 1 93.1 ± 21.9 79.2 ± 29.2 83.8 - 102.3 66.9 - 91.5 1 (4.2) 2 (8.3) 23 (95.8) 22 (91.7) 
Diarrhea 24 1 91.7 ± 14.8 87.5 ± 23.7 85.5 - 97.9 77.5 - 97.5 0 (0,0) 3 (12.5) 24 (100.0) 21 (87.5) 
Financial difficulties 24 1 62.5 ± 35.9 48.6 ± 19.6 47.3 - 77.6 40.3 - 56.9 11 (45.8) 12 (50.0) 13 (54.2) 12 (50.0) 
QLQ-H&N43 questionnaires           
Symptoms scales / items           
Pain 24 4 69.8 ± 28.4 49.6 ± 31.4 57.8 - 81.8 36.4 - 62.9 5 (20.8) 8 (33.3) 18 (75.0) 6 (25.0) 
Swallowing 24 4 81.9 ± 23.4 54.9 ± 32.9 72.1 - 91.8 40.9 - 68.8 2 (8.3) 11 (45.8) 19 (79.2) 12 (50.0) 
Sense problems 24 2 82.6 ± 28.0 50.0 ± 24.6 70.8 - 94.5 36.6 - 60.4 2 (8.3) 9 (37.5) 20 (83.3) 10 (41.7) 
Speech problems 24 4 78.1 ± 25.6 59.0 ± 29.4 67.3 - 88.9 46.6 - 71.4 3 (12.5) 6 (25.0) 17 (70.8) 12 (50.0) 
Trouble with social eating 24 5 78.3 ± 24.6 48.3 ± 25.9 67.9 - 88.7 37.4 - 59.3 2 (8.3) 6 (25.0) 18 (75.0) 6 (25.0) 
Trouble with social contact 24 1 73.6 ± 30.0 48.6 ± 34.0 57.5 - 89.7 34.2 - 62.9 7 (29.2) 12 (50.0) 17 (70.8) 12 (50.0) 
Teeth problems 24 2 81.9 ± 20.2 90.9 ± 14.7 73.4 - 90.5 84.8 - 97.2 1 (4.2) 0 (0.0) 21 (87.5) 23 (95.8) 
Opening mouth problems 24 1 79.2 ± 36.5 43.1 ± 33.3 63.7 - 94.6 28.9 - 57.1 5 (20.8) 14 (58.3) 19 (79.2) 10 (41.7) 
Dry mouth 24 1 40.3 ± 41.7 30.5 ± 21.8 22.7 - 57.9 21.3 - 39.7 15 (62.5) 20 (83.3) 9 (37.5) 4 (16.7) 
Sticky saliva 24 1 72.2 ± 38.9 49.9 ± 34.1 55.8 - 88.6 35.6 - 64.4 8 (33.3) 13 (54.2) 16 (66.7) 11 (45.8) 
Coughing 24 1 62.5 ± 37.2 62.5 ± 39.7 46.8 - 78.2 45.7 - 79.3 10 (41.7) 14 (58.3) 10 (41.7) 14 (58.3) 
Felt ill in neck and shoulder 24 2 57.6 ± 26.5 58.3 ± 28.6 46.5 - 68.8 46.2 - 70.4 5 (20.8) 6 (25.00) 11 (45.8) 14 (58.3) 
Weight loss 24 1 63.9 ± 37.9 47.2 ± 27.7 47.9 - 79.9 35.5 - 58.9 8 (33.3) 13 (54.2) 16 (66.7) 11 (45.8) 
Skin problems 24 3 83.8 ± 20.5 76.9 ± 11.8 75.2 - 92.4 71.9 - 81.8 1 (4.2) 1 (4.2) 20 (83.3) 23 (95.8) 
Wounds healing 24 1 90.3 ± 20.8 79.2 ± 25.7 81.5 - 99.1 68.3 - 90.0 2 (8.3) 2 (8.3) 22 (91.7) 22 (91.7) 
Anxiety 24 2 43.1 ± 35.8 41.0 ± 21.9 27.9 58.2 31.7 - 50.3 14 (58.3) 15 (62.5) 7 (29.2) 8 (33.3) 
Numbness in hands or feet 24 1 66.7 ± 36.8 55.6 ± 30.6 51.1 - 82.2 42.6 - 68.5 8 (33.3) 11 (45.8) 16 (66.7) 13 (54.2) 
*Correlation is significant at the 0.05 level  
** Correlation is significant at the 0.01 level 
 
Table 3. Spearman's correlation of time for diagnosis with global health and functional scales in QLQ-C30 
Variable 1 2 3 4 5 6 7 
Time for diagnosis -       
Global health / QoL 0.489* -      
Physical functioning -0.107 -0.470* -     
Role functioning 0.032 -0.594* 0.505* -    
Emotional functioning -0.180 -0.587** 0.566** 0.642** -   
Cognitive functioning -0.211 -0.714** 0.595** 0.714** 0.550** -  
Social functioning -0.078 0.584** 0.517** 0.645** 0.713** 0.501* - 
*Correlation is significant at the 0.05 level  
** Correlation is significant at the 0.01 level 
 
  







Table 4. Spearman's correlation of time for diagnosis with symptoms scales in QLQ-H&N 43 
Variable 1 2 3 4 5 6 7 8 9 
Time for diagnosis -         
Pain -0.049 -        
Swallowing -0.098 0.780** -       
Senses problems -0.393 0.260 0.370 -      
Speech problems -0.249 0.680** 0.513* 0.366 -     
Trouble with social eating -0.196 0.597** 0.535** 0.457* 0.663** -    
Trouble with social contact -0.211 0.728** 0.603** 0.153 0.770** 0.697** -   
Teeth problems -0.265 0.124 0.151 -0.021 0.352 0.029 0.280 -  
Opening mouth problems -0.131 0.627** 0.457* -0.012 0.618** 0.668** 0.726** 0.341 - 
Dry mouth -0.261 0.460* 0.275 -0.015 0.229 0.058 0.455* 0.016 0.325 
Sticky saliva -0.271 0.683** 0.467* 0.271 0.705** 0.599** 0.544** 0.227 0.457* 
Coughing -0.090 0.383 0.333 0.259 0.190 0.250 0.268 0.213 0.435* 
Felt ill in neck and shoulder -0.417* 0.289 0.112 0.055 0.210 0.214 0.175 0.197 0.260 
Weight loss 0.107 0.455* 0.148 0.126 0.435* 0.474* 0.315 0.026 0.401 
Skin problems 0.065 -0.051 0.329 0.326 0.071 0.186 0.108 -0.419* -0.195 
Wounds healing -0.217 0.214 0.137 0.251 0.468* 0.374 0.175 -0.035 0.076 
Anxiety -0.043 0.499* 0.101 0.085 0.466* 0.421* 0.442* 0.009 0.614** 
Numbness in hands or feet 0.078 0.187 0.101 0.181 0.079 0.149 0.021 -0.092 -0.019 
 10 11 12 13 14 15 16 17  
Time for diagnosis          
Pain          
Swallowing          
Senses problems          
Speech problems          
Trouble with social eating         
Trouble with social contact         
Teeth problems          
Opening mouth problems         
Dry mouth -         
Sticky saliva 0.078 -        
Coughing 0.021 0.167 -       
Felt ill in neck and shoulder 0.341 0.388 0.004 -      
Weight loss 0.128 0.329 -0.077 0.080 -     
Skin problems 0.009 0.025 0.101 0.105 0.042 -    
Wounds healing -0.005 0.494* -0.256 0.375 0.141 0.098 -   
Anxiety 0.160 0.226 0.261 -0.029 0.399 -0.295 0.131 -  
Numbness in hands or feet -0.292 0.041 0.141 0.172 0.184 0.082 0.066 0.288  
*. Correlation is significant at the 0.05 level 
**. Correlation is significant at the 0.01 level          
 
Table 5. Comparison of quality of life in nasopharyngeal carcinoma at first time in hospital and after diagnosis 
Scales Means (SD) 95% CI Sig 
QLQ-C30 questionnaires 
   
Global health status/QoL pre-post -14.9 (20.4) -23.53 - (-6.3) 0.002** 
Functional scales 
   
Physical functioning pre-post 24.9 (15.5) 18.4 - 31.5 0.000** 
Role functioning pre-post 23.6 (25.0) 13.0 - 34.2 0.000** 
Emotional functioning pre-post 2.8 (26.7) -8.5 - 14.0 0.615 
Cognitive functioning pre-post 11.1 (34.3) 4.9 - 33.9 0.017* 
Social functioning pre-post 19.4 (34.3) 4.9 - 33.9 0.011* 
Symptoms scales 
   
Fatigue pre-post 19.1 (25.5) 8.2 - 29.8 0.001** 
Nausea and vomiting pre-post 20.8 (33.8) 6.6 - 35.1 0.006** 
Pain pre-post 4.9 (41.3) -12.6 - 22.3 0.569 
Dyspnea pre-post -13.9 (33.9) -28.2 - 0.4 0.057 
Insomnia pre-post -1.4 (38.7) -17.7 - 14.9 0.862 
Appetite loss pre-post 33.3 (35.4) 18.4 - 48.3 0.000** 
Constipation pre-post 13.9 (37.9) -2.1 - 29.9 0.086 
Diarrhea pre-post 4.2 (29.9) -8.5 - 16.8 0.502 
Financial difficulties pre-post 13.9 (33.9) -0.5 - 28.2 0.057 
QLQ-H&N43 questionnaires 
   
Symptoms scales / items 
   
Pain pre-post 20.2 (30.4) 7.3 - 32.9 0.004** 
Swallowing pre-post 27.1 (35.5) 12.1 - 42.1 0.001** 
Sense problems pre-post 32.6 (27.1) 21.2 - 44.1 0.000** 
Speech problems pre-post 19.1 (27.6) 7.4 - 30.8 0.003** 
Trouble with social eating pre-post 29.9 (24.2) 19.8 - 40.2 0.000** 
Trouble with social contact pre-post 24.9 (35.8) 9.9 - 40.1 0.002** 
Teeth pre-post -9.0 (17.7) -16.5 - (-1.6) 0.020* 
Opening mouth pre-post 36.1 (33.9) 21.8 - 50.4 0.000** 
Dry mouth pre-post 9.7 (42.3) -8.1 - 27.6 0.271 
Sticky saliva pre-post 22.2 (37.7) 6.3 - 38.1 0.008** 
Coughing pre-post 0.0 (40.5) -17.1 - 17.1 1.000 
Felt ill in neck and shoulder pre-post -0.7 (26.2) -11.8 - 10.4 0.899 
Weight loss pre-post 16.7 (39.3) 0.1 - 33.3 0.049* 
Skin problems pre-post 6.9 (23.8) -3.1 - 16.9 0.167 
Wounds healing pre-post 11.1 (23.4) 1.2 - 20.9 0.029* 
Anxiety pre-post 2.1 (30.8) -10.9 - 15.1 0.743 
Numbness in hands or feet pre-post 11.1 (40.1) -5.8 - 28.1 0.188 
*Correlation is significant at the 0.05 level  
** Correlation is significant at the 0.01 level 
 
